Three years ago “menopause skincare” existed mostly in press releases. In 2026 it is one of the fastest-growing segments in UK beauty, with dedicated retail space at Boots and curated edits at Space NK. It is also the category where a lazy brief is most quickly exposed.
Why relabelling fails
The customer is not an extension of a 28-year-old’s routine. During perimenopause, declining and fluctuating oestrogen reduces sebum production, thins the epidermis, slows barrier recovery and can increase reactivity. Skin that tolerated a 10% acid serum at 35 may sting at 48.
She also reads. This is a customer who has researched her own symptoms, been dismissed by a GP, and can distinguish a formulation built for her from a product with “menopause-friendly” added to the carton copy.
What the formula actually has to do
| Skin change | Formulation response | Claim you can defend |
|---|---|---|
| Barrier compromise, water loss | Ceramides with cholesterol and fatty acids, glycerin, squalane, ectoin | Measured reduction in transepidermal water loss over 4–8 weeks |
| Increased reactivity | No drying alcohol, low or no fragrance, buffered pH, no daily strong acids | Tolerability data from a consumer panel, not a promise |
| Loss of firmness and density | Peptides, low-dose retinaldehyde or encapsulated retinol, adequate hydration | Instrumental firmness or elasticity improvement at the tested level |
| Dryness with occasional breakouts | Non-comedogenic emollients, lighter cream-gel textures | “Non-comedogenic” only where tested or formulation-justified |
| Disrupted sleep, stress | Texture and sensory experience that supports adherence | Consumer perception of comfort and calm — clearly labelled as perception |
What to leave out
- High fragrance load. The fastest way to lose a reactive customer in week two.
- Daily exfoliating acids. A weekly treatment is defensible; a daily 10% glycolic in a barrier-compromised routine is not.
- Aggressive “anti-ageing” language. This customer is not trying to reverse a decline; she is trying to maintain function. The framing that works is strength and self-knowledge.
- Borrowed efficacy data. A supplier’s in-vitro study on an ingredient is not a product claim. It supports a rationale; it does not replace a test on your formula.
The testing that makes the claim real
A credible file for this category usually includes instrumental measurement of hydration and transepidermal water loss, a firmness or elasticity assessment where that claim is made, and a consumer perception study with 40–60 participants in the target age band over four to eight weeks. That is four to ten weeks of calendar time and a four-figure budget — and it is the difference between a claim and a slogan.
Packaging and service design
Opaque or airless formats protect actives and suit a customer who is buying a treatment rather than a display object. Larger sizes are welcomed: this customer uses product consistently and resents running out. Clear dosing and a legible ingredient story on the outer carton do more for conversion than a metallic finish.
The category rewards specificity. Name the mechanism, state the concentration, show the measurement — and resist the temptation to medicalise.
An honest boundary
Perimenopause is a medical transition. A cosmetic can support the appearance and comfort of skin; it cannot treat symptoms, and any claim that implies otherwise moves the product into medicines regulation. Brands that respect that line build more durable trust than those that blur it.
Age band, skin changes observed, current routine and irritants, claims required, price point, pack format, volume, launch window. Without the first two, the formulator is designing for a demographic rather than a person.
Where this sits in a real project
This is formulation work rather than a marketing exercise; the bench, testing and documentation route is set out under formulation development. If we develop and license the formula it is an ODM project; if the brand, naming and pack are being built at the same time it is OBM incubation. Claim wording is reviewed against the UK compliance requirements before artwork.
Questions we are asked
Can an existing formula simply be relabelled for this audience?
Usually not credibly. The segment reads labels, and a repositioned generic base tends to fail on tolerance and texture rather than on the story. A short INCI list, fragrance-free systems and a finish that suits daily use matter more than the claims on the carton.
What evidence supports a claim in this category?
Instrumental hydration and barrier measurements, consumer panels, and compatibility and stability data on the final pack. The claim is written to match the evidence, not the other way round; where the data will not support a claim we say so before artwork.
Are retinoids always the right active?
Not for reactive or sensitised skin. Retinoid alternatives and barrier-first systems are often better tolerated, and the choice affects both the testing plan and the claims file. We decide it against the brief rather than the trend.